High-quality palliative care also requires special expertise in honest, compassionate communication. In addition to enhancing the patient's and family's experience, these skills help to establish trust and overcome barriers to adequate care and relief of symptoms. Several communication tasks are especially important: conveying accurate prognostic information while maintaining hope, eliciting information about symptoms, decision making about curative and palliative treatments, handling emotions, and dealing with requests from patients and families who have unrealistic goals [34, 35, 36] . The challenges of communicating effectively are discussed later in this course.
Equipoise – Boldenone Undecylenate (Bold200, Boldenone, Baldebal-H)
Ciccone Equipoise Combo450 (See Boldenone esters: Undecylenate, see Cypionate, Acetate)
Primabolin Tabs – Methenolone Acetate
Primabolin Depot – Methenolone Enathate (Alphabolin, Primabolin Depot)
Masteron100 – Drostanalone Propionate
Masteron200 – Drostanolone Enanthate
Winstrol Depot – Stanozolol
Winstrol Tabs – Stanozolol
Oxandrolone – Oxandrolone (Anavar)
Dienogest was synthesized in 1979 in Jena , Germany under the leadership of Kurt Ponsold, was initially referred to as STS-557 .   It was found that its potency was 10 times that of levonorgestrel .  The first product on the market to contain dienogest was a combined oral contraceptive pill (with ethinylestradiol), Valette, introduced in 1995 and made by Jenapharm .  In 2007, dienogest was introduced as Dinagest in Japan for the treatment of endometriosis, and it was subsequently marketed for this indication as Visanne in Europe and Australia in December 2009 and April 2010, respectively.  Qlaira was introduced in Europe in 2009 and Natazia was introduced in the United States in 2010.